Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ11191121-2,52
KB11911193-0,17
PKN108,9108,980,57
Msft-0,13
Nokia5,9986,0021,66
IBM1,10
Mercedes-Benz Group AG57,4957,52-0,19
PFE0,40
16.02.2026 10:50:51
Indexy online
AD Index online
select
AD Index online
 

  • 13.02.2026
TransMedics Grp Rg (NASDAQ Cons)
Závěr k 13.2.2026 Změna (%) Změna (USD) Objem obchodů (USD)
129,84 1,03 1,32 434 971
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 16.02.2026
Popis společnosti
Obecné informace
Název společnostiTransMedics Group Inc
TickerTMDX
Kmenové akcie:Ordinary Shares
RICTMDX.O
ISIN-
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky30.09.2025
Počet zaměstnanců k 31.12.2024 728
Akcie v oběhu k 17.10.2025 34 174 325
MěnaUSD
Konstituent indexůS&P 600 Small Cap
Kontaktní informace
Ulice200 Minuteman Road
MěstoANDOVER
PSČ01810
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon19 785 520 900

Business Summary: TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
Financial Summary: BRIEF: For the 39 weeks ended 30 September 2025, TransMedics Group Inc revenues increased 39% to $444.7M. Net income before extraordinary items increased from $28.6M to $83.6M. Revenues reflect OCS Liver net revenue segment increase of 51% to $332.9M, OCS Heart net revenue segment increase of 22% to $96.1M, United States segment increase of 41% to $429.8M, All other countries segment increase of 4% to $11.9M.
Odvětvová klasifikace
TRBC2012Advanced Medical Equipment & Technology (NEC)
MGINDUSTRYMedical Equipment & Supplies
MGSECTORHealthcare
NAICSElectromedical and Electrotherapeutic Apparatus Manufacturing
NAICSOther Nonscheduled Air Transportation
NAICS2007Electromedical Apparatus Mfg
NAICS1997Electromedical and Electrotherapeutic Apparatus Manufacturing
SICElectromedical Equipment
SICAir Transportation, Nonscheduled



  • Poslední aktualizace: 16.02.2026
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorWaleed Hassanein56
Chief Financial Officer, TreasurerGerardo Hernandez5402.12.202402.12.2024
Senior Vice President, General Counsel, Corporate SecretaryMatthew Forsyth-09.03.202609.03.2026
Senior Vice President, General Counsel, Corporate SecretaryAnil Ranganath44
Senior Vice President - Supply Chain and OperationsNicholas Corcoran43
Senior Vice President - InternationalTamer Khayal5602.02.2026
Chief Commercial OfficerGiovanni Cecere-02.02.202602.02.2026